ButenafineButenafine
MedChemExpress (MCE)
HY-114518
101828-21-1
KP363
Please store the product under the recommended conditions in the Certificate of Analysis.
Room temperature in continental US
may vary elsewhere.
Butenafine (KP363) is a potent and broad spectrum benzylamine antifungal agent. Butenafine inhibits fungal ergosterol biosynthesis at the point of squalene epoxidation, leading to a deficiency of the fungal cell membranes. Butenafine is effective against dermatophytes infections, such as tinea pedis, tinea cruris, tinea versicolor.
Butenafine demonstrates comparable activity against the dermatophytes with a MIC range of 0.03-0.25 μg/ml. It displays limited activity against the yeast Candida albicans and no activity against Malassezia furfur[1].Butenafine (25
50 or 100 μM) eliminates the promastigote forms of L. amazonensis and L. braziliensis in a dose-dependent manner, and shows EC50 values of 34.10±3.76 μM and 81.25±10.24 μM, respectively, in peritoneal macrophages from BALB/c mice. Butenafine induces mild cytotoxicity in peritoneal macrophages from BALB/c mice with a CC50 of 97.88 μM[1].
Butenafine (subcutaneous administration
1-100 mg/kg) to mice has no effect on the central and autonomic nervous systems. Topical administration of 0.3-3.0% butenafine solutions to guinea pigs also has no effect on the somatic nervous system[1].In primary therapeutic studies on guinea pigs, Butenafine (1% topical application
4-10 days
day 3 and 4 post-infection) exhibits a complete cure after 10 days in vivo-effect on dermatophytosis, T. mentagrophytes[1].Butenafine (0.125, 0.25, 0.5 and 1.0% topical application
q.d. or b.i.d. for 10 days
day 4 post-infection) exhibits a 100% cure after 0.5% or 1% application and has no difference in efficacy between 1% q.d. and b.i.d. in vivo-effect on dermatophytosis, T. mentagrophytes[1].
IC50: antifungal[1] In Vitro Butenafine demonstrates comparable activity against the dermatophytes with a MIC range of 0.03-0.25 μg/ml. It displays limited activity against the yeast Candida albicans and no activity against Malassezia furfur[1].Butenafine (25
50 or 100 μM) eliminates the promastigote forms of L. amazonensis and L. braziliensis in a dose-dependent manner, and shows EC50 values of 34.10±3.76 μM and 81.25±10.24 μM, respectively, in peritoneal macrophages from BALB/c mice. Butenafine induces mild cytotoxicity in peritoneal macrophages from BALB/c mice with a CC50 of 97.88 μM[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Butenafine Related Antibodies
| | | |
| | | | | |
[1]. Katrina Kokjohn, et al. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.Int J Dermatol. 2003 Sep
42 Suppl 1:11-7. [Content Brief]
[2]. Adriana Bezerra-Souza, et al. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. 2016 Dec
65(6 Pt A):702-707. [Content Brief]
[3]. Topical Antifungal Agent. Butenafine